Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, multiple-dose study of SGN-40 (anti-huCD40 mAb) in patients with refractory or recurrent multiple myeloma

Next Previous
X
Search
Trial Profile

A phase I, multiple-dose study of SGN-40 (anti-huCD40 mAb) in patients with refractory or recurrent multiple myeloma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dacetuzumab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Seagen; Seattle Genetics

    • Most Recent Events

    • 07 Oct 2011 Actual end date changed from Aug 2007 to Nov 2007 as reported by ClinicalTrials.gov.
    • 09 Oct 2008 Genentech reported as a Sponsor by ClinicalTrials.gov.
    • 09 Oct 2008 Actual end date was Aug 2007, according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top